Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business And Finance News, In Brief

Executive Summary

Study Finds Personalized Medicine Increasingly Emphasized In Oncology

You may also be interested in...



Eisai Makes Oncology Debut With Halaven, But Development Question Marks Remain

TOKYO - Eisai gained its first U.S. approval for one of its in-house developed oncology products, Halaven (eribulin), but the company's blockbuster expectations may be tempered by progression-free survival data that did not meet secondary endpoints

FDA's Seyfert-Margolis On Companion Diagnostics Guidance

Industry is anxiously awaiting guidance from FDA on the development of companion diagnostics for drugs that will inform efforts to move towards personalized medicine.

Finding Inspiration: Ipsen Builds Fourth Specialist Franchise With Hemophilia Deal

Deal in some ways mirrors Ipsen's July 2006 agreement with Tercica in endocrinology.

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel